Amgen's Kyprolis bests Velcade in new Phase III myeloma trial
This article was originally published in Scrip
Executive Summary
Amgen/ Onyx's second-generation proteasome inhibitor Kyprolis (carfilzomib) has doubled progression-free survival in patients with relapsed multiple myeloma in the head-to-head ENDEAVOR trial that pitted it against Takeda's older proteasome inhibitor bortezomib (Velcade).